The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2017 | Rigosertib in combination with azacitidine: a potential treatment for AML?
Shyamala Navada, MD, from Tisch Cancer Institute, New York, NY, US, talks to us about a Phase I/II trial evaluating the effectiveness of oral rigosertib in combination with azacitidine for the treatment of acute myeloid leukemia (AML) (NCT01926587). She describes the positive results of the trial, noting that the combination was found to be safe and well-tolerated and produced a high overall response rate in comparison to monotherapy, which supports their potential use for the treatment of AML in the future. This interview was filmed at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.
